Akso Health Group ADR(AHG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.02 | Insider Own | - | Shs Outstand | 854.0M | Perf Week | -3.08% |
| Market Cap | 1.08B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 22.9M | Perf Month | 23.53% |
| Enterprise Value | 1.08B | PEG | - | EPS next Q | - | Inst Own | 0.03% | Short Float | 0.3% | Perf Quarter | -5.26% |
| Income | -0.02B | P/S | 77.53 | EPS this Y | - | Inst Trans | 22.08% | Short Ratio | 0.64 | Perf Half Y | -41.12% |
| Sales | 0.01B | P/B | 5.97 | EPS next 5Y | - | ROA | -8.35% | Short Interest | 0.07M | Perf YTD | -23.17% |
| Book/sh | 0.21 | P/C | 6329.94 | EPS past 3/5Y | 24.09% 59.38% | ROE | -9.86% | 52W High | -49.6% ($2.50) | Perf Year | -24.63% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | 1.86% 51.13% | ROIC | -10.36% | 52W Low | 84.99% ($0.68) | Perf 3Y | -4.55% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 95.22% | Gross Margin | -8.39% | Volatility(W/M) | 9.81% 10.33% | Perf 5Y | -70.21% |
| Dividend TTM | - | EV/Sales | 77.69 | Sales Y/Y TTM | -6.2% | Oper. Margin | -28.93% | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | 2018/8/1 | Quick Ratio | 21.74 | EPS Q/Q | 40.26% | Profit Margin | -135.08% | RSI (14) | 53.77 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.77 | Sales Q/Q | 25.62% | SMA20 | -1.76% ($1.28) | Beta | -1.47 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.01 | Earnings | - | SMA50 | 23.59% ($1.02) | Rel Volume | 0.05 | Prev Close | $1.33 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -16.8% ($1.51) | Avg Volume(3M) | 0.11M | Price | $1.26 |
| IPO | 2017/11/3 | Option/Short | No/Yes | Trades | 114 | Volume | 4,899 | Change | -5.26% |
Akso Health Group is a small healthcare company based in China that previously operated a social e-commerce platform before pivoting its business into the medical sector. More recently, marketing promotional services have become the core driver of its revenue, and the company has identified expanding into U.S. cancer treatment and radiation oncology services as a new growth direction. Because its business structure has been changing rapidly, the stock carries the high volatility typical of companies in transition.
Over the past 1 year, roughly in the middle
50% below its 1-year high.
Traded less than usual. That is 5% of its average volume.
AHG has a sound balance sheet but weak earning power
Of every $100 in sales, $28.93 is lost.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $7,753. Peers typically go for $400.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -70.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
It ranks #5 of 10 in the industry
Based on market cap of $1B.
CAH#3 Cardinal Health Inc $58B PER 34.6 
HSIC#4 Henry Schein Inc $9B PER 24.7 AHG#5 Akso Health Group ADR $1B PER - 
FOCL#6 EDAP TMS SA ADR $157M PER - 
COSM#7 Cosmos Health Inc $31M PER - 
FAQ
What kind of company is AHG?
AHG belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of AHG?
The market cap of AHG is approximately $1.1B, ranking 2,520 within its sector.
What is the 52-week high and low for AHG?
AHG has recorded a 52-week high of $2.50 and a low of $0.68.
